Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


SNODGRASS H. RALPH Create: Alert

All | News | Filings
Date FiledTypeDescription
01/03/2022 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Granted 3,623 shares @ $1.6575, valued at $6k
09/03/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/18/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/02/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/04/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/01/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/27/2020 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Granted 150,000 options to buy @ $0.398, valued at $59.7k
11/21/2019 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Bought 15,000 shares @ $0.34, valued at $5.1k
10/22/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/28/2019 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Granted 150,000 options to buy @ $1, valued at $150k
03/14/2019 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Exercised 2,500 options to buy @ $1.5, valued at $3.8k
08/31/2018 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Disposed/sold 2,500 options to buy @ $10, valued at $25k
Granted 2,500 options to buy @ $1.5, valued at $3.8k
Disposed/sold 1,250 options to buy @ $10, valued at $12.5k
Granted 1,250 options to buy @ $1.5, valued at $1.9k
Disposed/sold 12,500 options to buy @ $10, valued at $125k
Granted 12,500 options to buy @ $1.5, valued at $18.8k
Disposed/sold 125,000 options to buy @ $3.49, valued at $436.3k
Granted 125,000 options to buy @ $1.5, valued at $187.5k
Disposed/sold 80,000 options to buy @ $3.8, valued at $304k
Granted 80,000 options to buy @ $1.5, valued at $120k
Disposed/sold 125,000 options to buy @ $1.96, valued at $245k
08/06/2018 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Granted 125,000 options to buy @ $1.27, valued at $158.8k
02/05/2018 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Granted 175,000 options to buy @ $1.16, valued at $203k
09/20/2017 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/28/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
11/10/2016 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Granted 80,000 options to buy @ $3.8, valued at $304k
06/21/2016 4 Form 4 - Statement of changes in beneficial ownership of securities
11/13/2015 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Disposed/sold 50,000 options to buy @ $12.8, valued at $640k
Granted 50,000 options to buy @ $7, valued at $350k
Disposed/sold 2,500 options to buy @ $10, valued at $25k
Granted 2,500 options to buy @ $7, valued at $17.5k
Disposed/sold 7,500 options to buy @ $10, valued at $75k
Granted 7,500 options to buy @ $7, valued at $52.5k
Disposed/sold 100,000 options to buy @ $10, valued at $1M
Granted 100,000 options to buy @ $7, valued at $700k
Disposed/sold 150,000 options to buy @ $9.25, valued at $1.4M
Granted 150,000 options to buy @ $7, valued at $1.1M
09/03/2015 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Granted 150,000 options to buy @ $9.25, valued at $1.4M
01/13/2015 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Granted 100,000 options to buy @ $10, valued at $1M
03/21/2014 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Acquired 50,000 warrants @ $0.5, valued at $25k
Acquired 150,000 warrants @ $0.5, valued at $75k
12/24/2013 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Disposed/sold 50,000 options to buy @ $1.13, valued at $56.5k
Granted 50,000 options to buy @ $0.5, valued at $25k
Disposed/sold 25,000 options to buy @ $1.13, valued at $28.3k
Granted 25,000 options to buy @ $0.5, valued at $12.5k
Disposed/sold 150,000 options to buy @ $1.65, valued at $247.5k
Granted 150,000 options to buy @ $0.5, valued at $75k
Disposed/sold 250,000 options to buy @ $1.5, valued at $375k
Granted 250,000 options to buy @ $0.5, valued at $125k
Disposed/sold 100,000 options to buy @ $1.93, valued at $193k
Granted 100,000 options to buy @ $0.5, valued at $50k
03/05/2013 4 Form 4 - Statement of changes in beneficial ownership of securities
12/22/2011 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on VistaGen Therapeutics, Inc.
Txns: Exercised 113,636 shares @ $0.88, valued at $100k
Exercised 113,636 options to buy @ $0
05/25/2011 4 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Excaliber Enterprises, Ltd.
Txns: Granted 545,416 shares @ $3.5, valued at $1.9M
Granted 56,818 options to buy @ $1.76, valued at $100k
Granted 3,181 options to buy @ $1.76, valued at $5.6k
Granted 20,000 options to buy @ $1.58, valued at $31.6k
Granted 12,500 options to buy @ $4.62, valued at $57.8k
Granted 25,000 options to buy @ $2.26, valued at $56.5k
Granted 12,500 options to buy @ $2.26, valued at $28.3k
Granted 75,000 options to buy @ $3, valued at $225k
Granted 125,000 options to buy @ $3, valued at $375k
Granted 50,000 options to buy @ $3.85, valued at $192.5k
05/25/2011 3 SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) has filed a Form 3 on Excaliber Enterprises, Ltd.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy